Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients
with her2 enriched subtype who achieved pCR after neoadjuvant treatment would have longer
survival. The neoadjuvant treatment for her2 positive patients include chemotherapy and
targeted therapy. Although the pCR rate was high to 60% after use of trastuzumab and
pertuzumab, but the adverse reaction of combined chemotherapy could not be negligible. Some
studies have attempted chemotherapy-free treatment for her2 positive patients during
neoadjuvant therapy. But, which patient could be exempted from chemotherapy and which drug
could be omitted are still unknow before treatment. Drug sensitivity screening in vitro was a
promising method for choosing chemotherapy. But there was no method could select effective
drugs accurately for breast cancer patients until now.
Previously, investigators developed a patient-derived tumor-like cell clusters in vitro
culture technology. Feasibility for guiding clinical treatment by drug sensitivity screening
based on this technology have been explored by preliminary exploration with a well
corresponding. And the results have been published. This study will explore whether drug
screening in vitro patient-derived tumor-like cell clusters from breast cancer tissue could
be a metheod for omitting chemotherapy for her2 positive participants.